Irinotecan
Pancreatic Polypeptide Tumor
Shaheen ShaguftaSmall moleculePhase 2Dormant
B
62/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 47/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the Pancreatic Polypeptide Tumor cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Temsirolimus University of Southern California | Phase 2 | B |
(+)-VINCRISTINE Shaheen Shagufta | Phase 2 | B |
Cediranib Academic and Community Cancer Research United | Phase 2 | B |
Everolimus Emory University | Phase 2 | B |
Capecitabine ECOG-ACRIN Cancer Research Group | Phase 2 | B |
View all 20 →
Same molecule, other indications
Irinotecan is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →